NewLimit raises $435M to take cell-reprogramming into humans
Armstrong-backed longevity firm reports age reversal in human liver cells, jumps to a $3.1B valuation and a first clinical trial
Summary
NewLimit, the cellular-reprogramming company co-founded by Coinbase CEO Brian Armstrong and Blake Byers, closed a $435M Series C on 2 June 2026 at a ~$3.1B valuation, led by Founders Fund with Eli Lilly Ventures joining the cap table. The raise funds its first human clinical trial, after a prototype medicine reversed cell age in old human liver cells. NewLimit's approach rewrites the epigenetic markers controlling gene expression without altering the underlying DNA sequence, distinct from gene-editing cuts. The data pulled the firm's clinical timeline forward by years against its own decade-plus forecast. It is one of 2026's largest longevity rounds, in a year on track for $8–9B in sector funding.
By the numbers
- $435M, Series C (Founders Fund-led; closed 2 Jun 2026).
- ~$3.1B, post-money valuation.
- $110M, Armstrong's personal seed investment (2021).
- ~$3.74B, longevity-sector funding in Q1 2026 alone (49 financings).
- $8–9B, projected full-year 2026 longevity funding.
Why it matters
Pharma money (Lilly) entering an epigenetic-reprogramming play signals the aging-biology thesis is maturing from venture science toward the clinic. Reprogramming that rejuvenates cells without cutting DNA could sidestep some gene-editing safety concerns, but human reprogramming carries its own oncogenic risks the first trial must clear.
What to watch
- Design and IND clearance of NewLimit's first human trial.
- Whether reprogramming holds up in vivo without tumour signals.
- More pharma entrants validating (or repricing) the longevity surge.